Pharmacology - CurrentMed (Page 4)

Pharmacology

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

PMCID: PMC12170901 PMID: 40523897 DOI: 10.1038/s41392-025-02274-z Journal: Signal transduction and targeted therapy Publication Date: 2025-6-17 Authors: Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, et al. Key Points * First study with the highest proportion of Asian mCRC patients receiving a KRAS G12C inhibitor, demonstrating promising anti-tumor

Pharmacology

The GPR88 Agonist RTI‐122 Reduces Alcohol‐Related Motivation and Consumption

PMCID: PMC12178211 PMID: 40536830 DOI: 10.1111/adb.70058 Journal: Addiction biology Publication Date: 2025-6-19 Authors: Lovelock DF, Liu W, Hamida SB, Cordero VL, Van Voorhies KJ, et al. Key Points * RTI-122 demonstrates a selective, receptor-specific mechanism for reducing alcohol consumption across multiple experimental models * Significant reductions in alcohol intake

Pharmacology

Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment

PMCID: PMC12178431 PMID: 40525920 DOI: 10.1167/iovs.66.6.56 Journal: Investigative ophthalmology & visual science Publication Date: 2025-6-17 Authors: Ji R, Ishikawa K, Tan W, Mori K, Tsukamoto R, et al. Key Points * Liposomal encapsulation of ripasudil dramatically improves drug retention and targeted delivery in ocular tissues * Lipo-Ripa

Pharmacology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment

PMCID: PMC12175699 PMID: 40526090 DOI: 10.18632/oncotarget.28744 Journal: Oncotarget Publication Date: 2025 Authors: Hernando-Calvo A, Kurzrock R, Gonzalez NS, Magidi S, Bresson C, et al. Key Points * Comprehensive molecular profiling revealed multiple actionable genetic alterations in mCRC * Personalized treatment strategies proposed, including targeted therapies matching specific mutations * Repeated

Pharmacology

Hitting Two Birds With One Stone: Dual Modulation of Brain Carbonic Anhydrases and Histone Deacetylases Boosts Memory Consolidation

PMCID: PMC12174897 PMID: 40528640 DOI: 10.1002/ardp.70020 Journal: Archiv der Pharmazie Publication Date: 2025-6-18 Authors: Costa A, Bozdag M, Renzi G, Rani B, Passani MB, et al. Key Points * Multi-targeted molecular approach shows promise for cognitive impairment treatment * Compounds 12 and 14 demonstrated memory enhancement at doses 10x

Pharmacology

Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

PMCID: PMC12175645 PMID: 40531439 DOI: 10.1002/prp2.70131 Journal: Pharmacology research & perspectives Publication Date: 2025-6-18 Authors: Hossain MS, Hussain MH Key Points * Multi-target drug design offers a more holistic approach to treating Alzheimer's disease by simultaneously addressing multiple pathological mechanisms * Emerging technologies like AI and nanomedicine

Pharmacology

Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: advances and challenges

PMCID: PMC12178025 PMID: 40533746 DOI: 10.1186/s12951-025-03528-2 Journal: Journal of nanobiotechnology Publication Date: 2025-6-18 Authors: Sanadgol N, Abedi M, Hashemzaei M, Kamran Z, Khalseh R, et al. Key Points * Exosomes provide a safer, more controllable alternative to cell-based therapies, eliminating risks like teratoma formation * Emerging strategies like cell-penetrating peptide

Pharmacology

A Double‐Blind Randomised Clinical Trial of Terbinafine‐Nanostructured Lipid Carriers: Should We Anticipate This Strategy for Effective Topical Treatment of Onychomycosis?

PMCID: PMC12171949 PMID: 40525269 DOI: 10.1111/myc.70076 Journal: Mycoses Publication Date: 2025-6-17 Authors: Parsay S, Saeedi M, Abastabar M, Hedayati MT, Rahimnia SM, et al. Key Points * Nanostructured lipid carriers enabled a more targeted and efficient delivery of terbinafine for onychomycosis treatment * Clinical severity index reduction of 45%